Fig. 6: Reversible lenalidomide OFF-switch control of a degradable CAR in vivo.

(A) Schematic of luciferase-tagged CAR constructs. (B) Experimental design for in vivo CAR depletion analysis: NSG mice were injected intravenously with 5 × 10⁶ Jurkat cells expressing the SD or mutSD CAR reporter; after engraftment, bioluminescent imaging was performed before and after one dose of 10 mg/kg pomalidomide administered by oral gavage. (C) Luminescence 24 hours before, 6 hours after, and 24 hours after pomalidomide. Two-way t-test, ## P < 0.005 at 6 hours post, P > 0.05 at other timepoints. (D) Bioluminescence flux (photons/s) of whole mice in each group, indicating CAR protein abundance. Data represent 1 of 2 independent experiments.